Evidence map›Paper›PMID 42598364›Full record

Trial reportFrontiers in nutrition2026

Precision synbiotic intervention with 2'-fucosyllactose and infant-derived

Ke Chen, Xi Zhang, Shanshan Jin, Jiayi Zhong, Haixia Chen, Genquan Yue, Yonghui Cheng, Rufeng Peng, Ziji Fang, Feitong Liu and 6 more

Erratum issuedAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Ke ChenDepartment of Clinical Nutrition, Chengdu Women's & Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xi ZhangDepartment of Clinical Nutrition, Chengdu Women's & Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Shanshan JinDepartment of Clinical Nutrition, Chengdu Women's & Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Jiayi ZhongDepartment of Clinical Nutrition, Chengdu Women's & Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Haixia ChenBaoxing Center for Disease Control and Prevention, Ya'an, China.
Genquan YueBaoxing Center for Disease Control and Prevention, Ya'an, China.
Yonghui ChengLongmen Town Central Health Center, Ya'an, China.
Rufeng PengBaoxing Maternal and Child Health Care Hospital, Ya'an, China.
Ziji FangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Feitong LiuH&H Group, China Research and Innovation Center, Guangzhou, China.
Zerong LuH&H Group, China Research and Innovation Center, Guangzhou, China.
Lingling ZhaoH&H Group, China Research and Innovation Center, Guangzhou, China.
Ruibiao HuH&H Group, China Research and Innovation Center, Guangzhou, China.
Xiaohan TaoH&H Group, China Research and Innovation Center, Guangzhou, China.
Qilin HeGraduate School of International Business, the Catholic University of Korea, Bucheon, Republic of Korea.
Changqi LiuSchool of Exercise and Nutritional Sciences, San Diego State University, San Diego, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Early childhood represents a critical window for nutritional programming of immune function and microbiome establishment. While human milk oligosaccharides (HMOs) and probiotics individually demonstrate health benefits, their synergistic integration as synbiotics remains underexplored in toddler populations. This study aimed to evaluate whether a precision synbiotic combining 2'-fucosyllactose (2'-FL) with infant-adapted Aim: To determine the efficacy of a 2'-FL-containing synbiotic on infectious and atopic disease incidence, gut microbiota composition, and intestinal immune markers in children aged 1-3 years. Methods: In this multicenter, double-blind, placebo-controlled, three-arm trial, 390 healthy toddlers were randomized (1:1:1) to receive: (1) synbiotic (2'-FL 1.0 g/day + Result: Synbiotic vs. placebo: URTI incidence reduced from 85.4 to 55.4% (adjusted risk ratio (aRR) 0.64, 95% CI 0.43-0.95; ARR 30.0%, NNT = 3.3; Conclusion: A 12-week precision synbiotic intervention combining 2'-FL with infant-derived Clinical trial registration: This study was registered in the Chinese Clinical Trial Registry (ChiCTR2400088943) prior to enrollment (https://www.chictr.org.cn/showprojEN.html?proj=235745).

Indexed as

2′-fucosyllactoseBifidobacteriumgut microbiotamucosal immunitysynbiotics

Identifiers

PMID42598364
PMCPMC13472563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.